Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

50.04 (USD) • At close September 6, 2024
Bedrijfsnaam Corbus Pharmaceuticals Holdings, Inc.
Symbool CRBP
Munteenheid USD
Prijs 50.04
Beurswaarde 602,676,756
Dividendpercentage 0%
52-weken bereik 3.033 - 61.9
Industrie Biotechnology
Sector Healthcare
CEO Dr. Yuval Cohen Ph.D.
Website https://www.corbuspharma.com

An error occurred while fetching data.

Over Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody

Vergelijkbare Aandelen

Oncternal Therapeutics, Inc. logo

Oncternal Therapeutics, Inc.

ONCT

3.98 USD

Biomerica, Inc. logo

Biomerica, Inc.

BMRA

0.347 USD

Terns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc.

TERN

7.81 USD

Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.

TPST

1.24 USD

AVROBIO, Inc. logo

AVROBIO, Inc.

AVRO

1.4 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)